Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Aug 6, 2025
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025.
Read more at globenewswire.com
